Tumor-associated macrophages (TAM) and inflammation in colorectal cancer

Cancer Microenvironment

Volumn 4, Issue 2, 2011, Pages 141-154

  Erreni, Marco ^a   Mantovani, Alberto ^a,b   Allavena, Paola ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Chemokines; Colorectal cancer; Cytokines; Inflammation; Tumor associated macrophages

Indexed keywords

CELL PROTEIN; CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 23; INTERLEUKIN 6; PROTEIN TIR8; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE FUNCTION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 81855166109     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-010-0052-5     Document Type: Article

References (168)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365:153-165 (Pubitemid 40091806)
2. Calvert PM, Frucht H (2002) The genetics of colorectal cancer. Ann Intern Med 137:603-612
3. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919-932 (Pubitemid 36298000)
4. Rustgi AK (2007) The genetics of hereditary colon cancer. Genes Dev 21:2525-2538 (Pubitemid 47607664)
5. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP (2006) Microsatellite instability in colorectal cancer. Br J Surg 93:395-406
6. Laghi L, Bianchi P, Malesci A (2003) Gender difference for promoter methylation pattern of hMLH1 and p16 in sporadic MSI colorectal cancer. Gastroenterology 124:1165-1166 (Pubitemid 36389819)
7. Westra JL, Plukker JT, Buys CH, Hofstra RM (2004) Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers. Clin Colorectal Cancer 4:252-259 (Pubitemid 40012321)
8. Malesci A et al. (2007) Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 13:3831-3839 (Pubitemid 47037588)
9. Prall F et al. (2004) Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 35:808-816 (Pubitemid 38903073)
10. Dolcetti R et al. (1999) High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 154:1805-1813 (Pubitemid 29262862)
11. Banerjea A et al. (2004) Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 3:21
12. Muller A, Fishel R (2002) Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Invest 20:102-109 (Pubitemid 34151064)
13. Wang D, Dubois RN, Richmond A (2009) The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol 9:688-696
14. Meira LB et al. (2008) DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 118:2516-2525 (Pubitemid 351949779)
15. Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26:373-400 (Pubitemid 350115102)
16. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545 (Pubitemid 32173595)
17. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217 (Pubitemid 40568680)
18. DeNardo DG, Johansson M, Coussens LM (2008) Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27:11-18
19. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancerrelated inflammation. Nature 454:436-444
20. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759 (Pubitemid 41400849)
21. Witz IP (2009) The tumor microenvironment: the making of a paradigm. Cancer Microenviron 2(Suppl 1):9-17
22. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142 (Pubitemid 47010839)
23. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603-1613 (Pubitemid 46710123)
24. Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447-458 (Pubitemid 39469981)
25. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancerimmune evasion in human melanoma cells. J Exp Med 203:1651-1656 (Pubitemid 44036269)
26. Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI (2006) The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev 20:2527-2538 (Pubitemid 44396838)
27. Borrello MG et al. (2005) Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A 102:14825-14830 (Pubitemid 41457140)
28. Germano G et al. (2010) Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70:2235-2244
29. Guerra C et al. (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291-302 (Pubitemid 46349841)
30. Bierie B, Moses HL (2006) TGF-beta and cancer. Cytokine Growth Factor Rev 17:29-40
31. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307-311 (Pubitemid 37158407)
32. Schioppa T et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198:1391-1402 (Pubitemid 37392484)
33. Gupta RB et al. (2007) Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133:1099-1105, quiz 1340-1 (Pubitemid 47494461)
34. Itzkowitz SH, Harpaz N (2004) Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126:1634-1648 (Pubitemid 38649879)
35. Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a populationbased study. Cancer 91:854-862 (Pubitemid 32173312)
36. Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138:2101-2114.e5
37. Bottazzi B et al. (1983) Regulation of the macrophage content of neoplasms by chemoattractants. Science 220:210-212 (Pubitemid 13115270)
38. Rollins BJ, Sunday ME (1991) Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 11:3125-3131 (Pubitemid 21895699)
39. Negus RP et al. (1995) The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 95:2391-2396
40. Opdenakker G, Van Damme J (1992) Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Today 13:463-464
41. Mantovani A, Bonecchi R, Locati M (2006) Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 6:907-918 (Pubitemid 44851733)
42. McConnell BB, Yang VW (2009) The role of inflammation in the pathogenesis of colorectal cancer. Curr Colorectal Cancer Rep 5:69-74
43. Popivanova BK et al. (2009) Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 69:7884-7892
44. Erreni M et al. (2009) Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol 460:105-121
45. Kim J et al. (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744-2753 (Pubitemid 46179464)
46. Schimanski CC et al. (2005) Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11:1743-1750 (Pubitemid 40471835)
47. Gunther K et al. (2005) Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int J Cancer 116:726-733 (Pubitemid 41099704)
48. Kawada K et al. (2007) Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26:4679-4688 (Pubitemid 47067410)
49. Sturm A, Baumgart DC, d'Heureuse JH, Hotz A, Wiedenmann B, Dignass AU (2005) CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 29:42-48 (Pubitemid 39576701)
50. Zipin-Roitman A et al. (2007) CXCL10 promotes invasionrelated properties in human colorectal carcinoma cells. Cancer Res 67:3396-3405 (Pubitemid 46724880)
51. Vetrano S et al. (2010) The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Gut 59:197-206
52. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361-371
53. Popivanova BK et al. (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560-570 (Pubitemid 351206546)
54. Greten FR et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296 (Pubitemid 39061110)
55. Pikarsky E et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466 (Pubitemid 39329586)
56. Fukata M, Abreu MT (2008) Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 27:234-243
57. Rakoff-Nahoum S, Medzhitov R (2007) Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124-127 (Pubitemid 47056471)
58. Huang B et al. (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009-5014 (Pubitemid 40827306)
59. Thomassen E, Renshaw BR, Sims JE (1999) Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11:389-399 (Pubitemid 29259633)
60. Mantovani A, Locati M, Polentarutti N, Vecchi A, Garlanda C (2004) Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR. J Leukoc Biol 75:738-742 (Pubitemid 38580052)
61. Polentarutti N et al. (2003) Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw 14:211-218 (Pubitemid 38122227)
62. Wald D et al. (2003) SIGIRR, a negative regulator of Tolllike receptor-interleukin 1 receptor signaling. Nat Immunol 4:920-927 (Pubitemid 37098664)
63. Garlanda C et al. (2004) Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A 101:3522-3526 (Pubitemid 38338228)
64. Garlanda C et al. (2007) Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res 67:6017-6021 (Pubitemid 47037479)
65. Iglesias D, Nejda N, Azcoita MM, Schwartz SJ, Gonzalez-Aguilera JJ, Fernandez-Peralta AM (2009) Effect of COX2-765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 20:1421-1429
66. Arber N et al. (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895 (Pubitemid 44315981)
67. Benelli R (2007) Aspirin, COX-2, and the risk of colorectal cancer. N Engl J Med 357:824-825, author reply 824-5
68. Pereira C, Medeiros RM, Dinis-Ribeiro MJ (2009) Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol 21:76-91
69. Cross JT, Poole EM, Ulrich CM (2008) A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J 8:237-247 (Pubitemid 352042411)
70. Hoebe K, Janssen E, Beutler B (2004) The interface between innate and adaptive immunity. Nat Immunol 5:971-974 (Pubitemid 41057712)
71. Kishimoto T (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23:1-21 (Pubitemid 40563163)
72. McLoughlin RM et al. (2003) Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 112:598-607 (Pubitemid 38056344)
73. Mantovani A, Sica A, Locati M (2005) Macrophage polarization comes of age. Immunity 23:344-346 (Pubitemid 41443435)
74. Atreya R et al. (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6:583-588 (Pubitemid 30305911)
75. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H (2000) Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151:31-38 (Pubitemid 30155582)
76. Hsu CP, Chung YC (2006) Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancer Res 26:4607-4614
77. Brozek W, Bises G, Girsch T, Cross HS, Kaiser HE, Peterlik M (2005) Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur J Cancer 41:2347-2354 (Pubitemid 41415612)
78. Knupfer H, Preiss R (2010) Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Colorectal Dis 25:135-140
79. Naugler WE et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121-124 (Pubitemid 47056470)
80. Grivennikov S et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-113
81. Bollrath J et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15:91-102
82. Bromberg J, Wang TC (2009) Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15:79-80
83. Saraiva M, O'Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170-181
84. Sandel MH et al. (2005) Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol 42:541-546 (Pubitemid 39655966)
85. Coca S et al. (1997) The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79:2320-2328 (Pubitemid 27251014)
86. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000) Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 88:1544-1548 (Pubitemid 30183138)
87. Nagtegaal ID et al. (2001) Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer 1:7
88. Gounaris E et al. (2007) Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A 104:19977-19982
89. Canna K et al. (2005) The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92:651-654 (Pubitemid 40460599)
90. Chiba T et al. (2004) Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 91:1711-1717 (Pubitemid 39546145)
91. Naito Y et al. (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491-3494 (Pubitemid 28376536)
92. Galon J et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964 (Pubitemid 44498003)
93. Pages F et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666 (Pubitemid 41817714)
94. Laghi L et al. (2009) CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10:877-884
95. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. Immunol Today 13:265-270
96. Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66:1-9 (Pubitemid 351324128)
97. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71-78 (Pubitemid 38082155)
98. Dinapoli MR, Calderon CL, Lopez DM (1996) The altered tumoricidal capacity of macrophages isolated from tumorbearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med 183:1323-1329
99. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555 (Pubitemid 35223554)
100. Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42:717-727
101. Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263-266 (Pubitemid 43121975)
102. Fu YX, Cai JP, Chin YH, Watson GA, Lopez DM (1992) Regulation of leukocyte binding to endothelial tissues by tumorderived GM-CSF. Int J Cancer 50:585-588
103. Yaal-Hahoshen N et al. (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12:4474-4480 (Pubitemid 44297794)
104. Scholl SM, Crocker P, Tang R, Pouillart P, Pollard JW (1993) Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? Mol Carcinog 7:207-211 (Pubitemid 23200885)
105. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23-35 (Pubitemid 37328697)
106. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5:953-964 (Pubitemid 41746764)
107. Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180:2011-2017
108. Goerdt S, Orfanos CE (1999) Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10:137-142 (Pubitemid 29115619)
109. O'Sullivan C, Lewis CE (1994) Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol 172:229-235 (Pubitemid 24151973)
110. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629 (Pubitemid 26338061)
111. Mantovani A (1994) Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest 71:5-16 (Pubitemid 24246016)
112. Konur A, Kreutz M, Knuchel R, Krause SW, Andreesen R (1998) Cytokine repertoire during maturation of monocytes to macrophages within spheroids of malignant and non-malignant urothelial cell lines. Int J Cancer 78:648-653 (Pubitemid 28507192)
113. Wyckoff JB et al. (2007) Direct visualization of macrophageassisted tumor cell intravasation in mammary tumors. Cancer Res 67:2649-2656 (Pubitemid 46548952)
114. Kaplan RN et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827 (Pubitemid 41753060)
115. Kaplan RN, Rafii S, Lyden D (2006) Preparing the "soil": the premetastatic niche. Cancer Res 66:11089-11093
116. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25:315-322 (Pubitemid 44922352)
117. Bronte V, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5:641-654 (Pubitemid 41113195)
118. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174
119. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179:977-983
120. Gounaris E et al. (2008) Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One 3:e2916
121. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540-550 (Pubitemid 38868623)
122. Steidl C et al. (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885
123. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13:1472-1479 (Pubitemid 46450437)
124. Ohno S et al. (2003) The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23:5015-5022 (Pubitemid 38182119)
125. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW (2002) Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62:7042-7049 (Pubitemid 35424099)
126. Jedinak A, Dudhgaonkar S, Sliva D (2010) Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 215:242-249
127. Xu L et al. (2009) Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69:7905-7910
128. Popovic ZV et al. (2007) Sulfated glycosphingolipid as mediator of phagocytosis: SM4s enhances apoptotic cell clearance and modulates macrophage activity. J Immunol 179:6770-6782
129. Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C (2004) Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol 172:4630-4636 (Pubitemid 38375282)
130. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7:415-428 (Pubitemid 46809165)
131. Massague J (2008) TGFbeta in cancer. Cell 134:215-230
132. Reinacher-Schick A et al. (2004) Loss of Smad4 correlates with loss of the invasion suppressor E-cadherin in advanced colorectal carcinomas. J Pathol 202:412-420 (Pubitemid 38456159)
133. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174:175-183 (Pubitemid 44079853)
134. Illemann M et al. (2006) MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4:293-302 (Pubitemid 43837330)
135. Kaler P, Godasi BN, Augenlicht L, Klampfer L (2009) The NF-kappaB/AKT-dependent induction of Wnt signaling in colon cancer cells by macrophages and IL-1beta. Cancer Microenviron
136. Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signaling. Cell 103:311-320
137. Segditsas S, Tomlinson I (2006) Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25:7531-7537 (Pubitemid 44885752)
138. Pancione M et al. (2009) Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 40:714-725
139. Ohtani H, Naito Y, Saito K, Nagura H (1997) Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity? Lab Invest 77:231-241
140. Sugita J et al. (2002) Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions. Jpn J Cancer Res 93:320-328 (Pubitemid 34464369)
141. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM (2003) Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 97:960-968 (Pubitemid 36173146)
142. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE (2003) Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 10:309-313
143. Zhou Q et al. (2010) The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 8:13
144. Bailey C et al. (2007) Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis 24:121-130 (Pubitemid 46669245)
145. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M (2009) Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 70:325-330
146. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360 (Pubitemid 38680426)
147. Gabrilovich DI et al. (2007) The terminology issue for myeloidderived suppressor cells. Cancer Res 67:425, author reply 426 (Pubitemid 46142802)
148. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942-949 (Pubitemid 47300008)
149. Manel N, Unutmaz D, Littman DR (2008) The differentiation of human T (H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9:641-649 (Pubitemid 351714729)
150. Santarlasci V et al. (2009) TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 39:207-215
151. Das J et al. (2009) Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med 206:2407-2416
152. Langrish CL et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233-240 (Pubitemid 40189432)
153. Buonocore S et al. (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464:1371-1375
154. Wang YQ et al. (2003) Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 105:820-824
155. Langowski JL et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442:461-465 (Pubitemid 44264796)
156. Stanilov N, Miteva L, Mintchev N, Stanilova S (2009) High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. Int J Colorectal Dis 24:151-157
157. Colonna M (2009) Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 31:15-23
158. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357-359
159. Lee JW et al. (2008) Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 181:6536-6545
160. Bettelli E et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238
161. Veldhoen M, Stockinger B (2006) TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. Trends Immunol 27:358-361 (Pubitemid 44038659)
162. Savage ND et al. (2008) Human anti-inflammatory macrophages induce Foxp3+ GITR+CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J Immunol 181:2220-2226
163. Izcue A, Coombes JL, Powrie F (2009) Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 27:313-338
164. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D (2006) In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 4:52
165. Salama P et al. (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186-192
166. Erdman SE et al. (2005) CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65:3998-4004 (Pubitemid 40775635)
167. Chaput N et al. (2009) Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58:520-529
168. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC (2010) Regulatory T cells in cancer. Adv Cancer Res 107:57-117